Market revenue in 2023 | USD 158.7 million |
Market revenue in 2030 | USD 515.8 million |
Growth rate | 18.3% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.51% in 2023. Horizon Databook has segmented the Japan crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Changes in regulatory policies pertaining to gene editing, coupled with rapid adoption of advanced technologies by the country have resulted in its significant market share. In April 2016, the Japanese government’s bioethics panel approved DNA modification in human embryos of up to two weeks for basic research purposes.
In February 2019, in accordance with the Japanese Cartagena Act government, the government stated that genome-edited end products established from the modifications of SDN-1 type, a direct mutation, are not regarded as living modified organisms.
In August 2018, a Japanese government panel regulated only genetically modified organisms, where foreign genes are induced permanently, implying that the production of gene edited organisms will not require government approval.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into Japan crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account